Atopic dermatitis - PubMed (original) (raw)
Review
Atopic dermatitis
Stephan Weidinger et al. Nat Rev Dis Primers. 2018.
Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life. AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course. AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as asthma and allergic rhinitis). Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations. Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration. The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption. Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch. Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants. Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.
Similar articles
- Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Zane LT, et al. Immunotherapy. 2016 Jul;8(8):853-66. doi: 10.2217/imt-2016-0023. Epub 2016 Jun 10. Immunotherapy. 2016. PMID: 27283509 Review. - Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies.
Mandlik DS, Mandlik SK. Mandlik DS, et al. Immunopharmacol Immunotoxicol. 2021 Apr;43(2):105-125. doi: 10.1080/08923973.2021.1889583. Epub 2021 Feb 28. Immunopharmacol Immunotoxicol. 2021. PMID: 33645388 Review. - Novel Therapeutic Approaches to Atopic Dermatitis.
Osinka K, Dumycz K, Kwiek B, Feleszko W. Osinka K, et al. Arch Immunol Ther Exp (Warsz). 2018 Jun;66(3):171-181. doi: 10.1007/s00005-017-0487-1. Epub 2017 Aug 31. Arch Immunol Ther Exp (Warsz). 2018. PMID: 28861617 Review. - Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R, Bozkaya D, Levenberg M, Faulkner S, Smith TW, Gerber RA. Clark R, et al. J Med Econ. 2018 Aug;21(8):770-777. doi: 10.1080/13696998.2018.1470520. Epub 2018 May 21. J Med Econ. 2018. PMID: 29706103 - Phosphodiesterase 4 inhibitors.
Zebda R, Paller AS. Zebda R, et al. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S43-S52. doi: 10.1016/j.jaad.2017.11.056. Epub 2017 Dec 15. J Am Acad Dermatol. 2018. PMID: 29248522 Review.
Cited by
- Pathophysiological Mechanisms of the Onset, Development, and Disappearance Phases of Skin Eruptions in Chronic Spontaneous Urticaria.
Seirin-Lee S, Takahagi S, Hide M. Seirin-Lee S, et al. Bull Math Biol. 2024 Nov 14;87(1):1. doi: 10.1007/s11538-024-01380-3. Bull Math Biol. 2024. PMID: 39541050 Free PMC article. - Unveiling the Impact of Moderate and Severe Atopic Dermatitis: Insights on Burden, Clinical Characteristics, and Healthcare Resource Utilization in Adult Greek Patients from the APOLO Cross-Sectional Study.
Stratigos AJ, Chasapi V, Katoulis A, Vakirlis E, Psarros F, Georgiou S, Vourdas D, Makris M, Lazaridou E, Gregoriou S, Skiadas I, Nakou M, Koulias C, Apolo Study Group. Stratigos AJ, et al. J Clin Med. 2024 Oct 23;13(21):6327. doi: 10.3390/jcm13216327. J Clin Med. 2024. PMID: 39518471 Free PMC article. - Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis.
Yoo SA, Kim KC, Lee JH. Yoo SA, et al. Int J Mol Sci. 2024 Oct 15;25(20):11064. doi: 10.3390/ijms252011064. Int J Mol Sci. 2024. PMID: 39456844 Free PMC article. - Unmet Medical Needs and Early Referral of Pediatric Atopic Dermatitis: An Expert Modified Delphi Consensus from Saudi Arabia.
Alradaddi A, Al Twaim A, Abu-Aliat A, Al-Atass K, Alogayell L, Aldayil M, AlBreiki S, Abed S, Fatani M, Alsharif O, Darwesh B, Gunay LM, Al-Khenaizan S. Alradaddi A, et al. Dermatol Res Pract. 2022 Aug 11;2022:5636903. doi: 10.1155/2022/5636903. eCollection 2022. Dermatol Res Pract. 2022. PMID: 39444785 Free PMC article. - Molecular and cellular mechanisms of itch sensation and the anti-itch drug targets.
Sun M, Chen ZR, Ding HJ, Feng J. Sun M, et al. Acta Pharmacol Sin. 2024 Oct 18. doi: 10.1038/s41401-024-01400-x. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39424975 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials